GlassScriptPhysician profile
Tonya M Carter
NPI 1720218654
$4,668.31
in general payments reported to CMS, 2019-2025
35 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.12 · 2022: $41.97 · 2023: $1,285 · 2024: $1,674 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,610.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $909.28 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $480.75 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $450.93 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Gilead Sciences, INC. | $372.96 | 2024-2025 | |
| Lilly USA, LLC | $352.35 | 2022-2025 | Jardiance, Mounjaro, Emgality |
| Exact Sciences Corporation | $220.84 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.20 | 2023-2025 | Jardiance |
| Abbvie INC. | $216.18 | 2023-2025 | |
| Astellas Pharma US INC | $160.00 | 2023-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $151.86 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $133.80 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $119.57 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $100.33 | 2023-2025 | Accrufer |
| Seqirus USA INC | $97.22 | 2023-2024 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Boston Scientific Corporation | $83.31 | 2023-2025 | Bodyguardian |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.